Addex Therapeutics Ltd
ADXN
$9.00
$0.19172.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -99.02% | -83.24% | -81.83% | -50.67% |
| Total Other Revenue | 4,837.50% | -100.00% | 205.88% | -- | 33.33% |
| Total Revenue | -70.60% | -99.02% | -81.89% | -81.87% | -50.47% |
| Cost of Revenue | -38.09% | -55.79% | -57.45% | 15.32% | 1.59% |
| Gross Profit | -708.55% | -1,421.82% | 7.55% | -165.12% | -104.39% |
| SG&A Expenses | -34.83% | -47.61% | -17.30% | -8.73% | 34.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.61% | -48.99% | -35.57% | -1.91% | 24.48% |
| Operating Income | 25.18% | 38.44% | 15.20% | -125.66% | -126.88% |
| Income Before Tax | -94.86% | -33.59% | -119.47% | -177.76% | -110.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.86% | -33.59% | -119.47% | -177.76% | -110.25% |
| Earnings from Discontinued Operations | -- | 99.18% | 99.87% | 761.64% | -22.19% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.60% | 57.44% | 40.30% | 578.56% | -35.73% |
| EBIT | 25.18% | 38.44% | 15.20% | -125.66% | -126.88% |
| EBITDA | 25.17% | 41.50% | 22.20% | -98.90% | -127.86% |
| EPS Basic | 53.87% | 62.57% | 53.00% | 451.70% | 14.82% |
| Normalized Basic EPS | -92.59% | -17.81% | -72.31% | -104.00% | -31.71% |
| EPS Diluted | 53.87% | 62.57% | 40.97% | 427.09% | 14.82% |
| Normalized Diluted EPS | -92.59% | -17.81% | -72.31% | -20.00% | -31.71% |
| Average Basic Shares Outstanding | 0.83% | 13.90% | 27.20% | 36.18% | 59.24% |
| Average Diluted Shares Outstanding | 0.83% | 13.90% | 27.20% | 132.71% | 59.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |